Opinion|Videos|December 12, 2025
Adherence and Persistence
Panelists discuss how improving adherence to LDL-lowering therapies is essential for sustained cardiovascular protection.
Advertisement
Episodes in this series
Panelists discuss how adherence to low-density lipoprotein (LDL)–lowering therapy, particularly injectables, remains one of the greatest challenges to long-term success. Patients often discontinue treatment due to side effects, inconvenience, or lack of follow-up support.
Pharmacists and health systems can play a key role in monitoring persistence, providing reminders, and counseling patients about the benefits of sustained therapy.
Panelists emphasize that simplifying treatment regimens and enhancing digital engagement could improve adherence and outcomes.
Advertisement
Related to this article
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5